P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY

MLA

J. Sanz-Caballer, et al. “P1339: Clinical Outcomes of Patients with Ebv+ Ptld Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study.” HemaSphere, vol. 6, June 2022, pp. 1224–25. EBSCOhost, https://doi.org/10.1097/01.HS9.0000848220.74181.5a.

APA

J. Sanz-Caballer, J. Storek, G. Socié, D. Thirumalai, N. Guzman-Beccera, P. Xun, D. Kumar, N. Sadetsky, D. Dierickx, J. Reitan, A. Barlev, & M. Mohty. (2022). P1339: Clinical Outcomes of Patients with Ebv+ Ptld Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study. HemaSphere, 6, 1224–1225. https://doi.org/10.1097/01.HS9.0000848220.74181.5a

Chicago

J. Sanz-Caballer, J. Storek, G. Socié, D. Thirumalai, N. Guzman-Beccera, P. Xun, D. Kumar, et al. 2022. “P1339: Clinical Outcomes of Patients with Ebv+ Ptld Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study.” HemaSphere 6 (June): 1224–25. doi:10.1097/01.HS9.0000848220.74181.5a.